Screener
Prime Medicine PRME Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -373.3%-218pp | -216.1%-101pp | -146.8%-9.9pp | -112.3%+2.0pp | -154.8%-55.2pp | |
| Return on invested capital | -192.4%-47.7pp | -175.4%-38.7pp | —— | -138.9%+40.5pp | -144.7%+15.8pp | |
| Liquidity | ||||||
| Current ratio | 3.1×-0.5× | 3.8×-1.0× | 4.8×-0.7× | 6.6×+0.1× | 3.6×-4.7× | |
| Leverage | ||||||
| Debt-to-equity | 2.8×+0.9× | 1.5×+0.4× | 1×+0.7× | 0.7×+0.5× | 2×+1.8× | |
| Per Share | ||||||
| Book value per share | $0.22-52.3% | $0.43-47.0% | $0.81-37.1% | $1.01-36.3% | $0.47-71.4% | |
| Valuation | ||||||
| Market capitalization | $558.64M-10.7% | $628.32M+141% | $626.37M+63.5% | $987.64M+114% | $283.6M-53.7% | |
| Price / book | 14×+3.8× | 8.2×+5.8× | 5.2×+2.7× | 6.1×+3.7× | 4.7×+1.5× |
FAQ
- Where do Prime Medicine's ratios come from?
- Every ratio is computed from Prime Medicine's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.